Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

08-06-2018 | Pancreatic cancer | ASCO 2018 | Video

Researcher comment: Neoadjuvant chemoradiotherapy beneficial for resectable pancreatic cancer

Preliminary findings from the PREOPANC-1 trial suggest that neoadjuvant chemoradiotherapy may be beneficial for patients with resectable pancreatic cancer. Lead author Geertjan Van Tienhoven outlines the results and discusses the challenges of conducting this trial. (3:46)

Watch the accompanying expert commentary.

More on this topic

06-06-2018 | Gastrointestinal cancers | ASCO 2018 | Video

Expert commentary: GI highlights including the PRODIGE 7, PRODIGE 24, and PREOPANC trials

Image Credits